Details for Patent: 8,829,013

Which drugs does patent 8,829,013 protect, and when does it expire?

Patent 8,829,013 protects JAKAFI and is included in one NDA.

Protection for JAKAFI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-eight patent family members in forty-one countries.

Summary for Patent: 8,829,013

Title:	Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Abstract:	The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Li; Hui-Yin (Hockessin, DE)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	14/256,311
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,829,013
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Analyzing the Scope and Claims of United States Patent 8,829,013

Introduction

United States Patent 8,829,013, assigned to Incyte Corporation and Incyte Holdings Corporation, is a significant patent in the field of pharmaceuticals, particularly focusing on inhibitors for JAK2 tyrosine kinase. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Patent Number and Date

• The patent number is 8,829,013, granted on September 10, 2013[2].

Inventors and Assignees

• The inventors include Yun-Long Li, James D. Rodgers, and others associated with Incyte Corporation and Incyte Holdings Corporation, both based in Wilmington, DE[2].

Background and Field of the Invention

• The patent pertains to the development of inhibitors for JAK2 (Janus Kinase 2) tyrosine kinase, which is crucial in treating myeloproliferative disorders such as polycythemia vera (PV) and essential thrombocythemia (ET)[2].

Scope of the Patent

Claim Structure

• The patent includes multiple claims, both independent and dependent, which define the scope of the invention. Independent claims typically outline the broadest aspects of the invention, while dependent claims narrow down to specific embodiments[3].

Independent Claim Length and Count

• Research suggests that the length and count of independent claims are critical metrics for measuring patent scope. Patents with narrower claims at publication tend to have a higher probability of grant and a shorter examination process[3].

Claims Analysis

Independent Claims

• The independent claims in this patent focus on the chemical structure of the JAK2 inhibitors, specifying the heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines. These claims define the core compounds and their derivatives that are covered under the patent[2].

Dependent Claims

• Dependent claims further detail specific aspects of the compounds, such as particular substituents, pharmaceutical compositions, and methods of use. These claims help to protect various embodiments of the invention and ensure comprehensive coverage[2].

Patent Landscape

Related Patents and Prior Art

• The patent cites numerous prior art documents, including other patents and applications related to JAK2 inhibitors. This extensive list indicates a highly competitive and innovative field where multiple entities are actively developing similar technologies[2].

Continuation and Divisional Applications

• The patent is part of a series of continuation and divisional applications, indicating a strategic approach by Incyte Corporation to broaden and deepen their patent portfolio in this area. For example, it is a continuation of application No. 13/076,220, which is itself a continuation of earlier applications[4].

Examination Process and Patent Quality

Examination Duration and Scope Narrowing

• The examination process for this patent, as with many others, likely involved narrowing the scope of the claims to ensure clarity and validity. Research indicates that longer examination durations often result in narrower claims, which can improve the overall quality of the patent[3].

Patent Maintenance and Forward Citations

• The maintenance of this patent and its forward citations can provide insights into its impact and relevance within the industry. Patents that are frequently cited by later patents are generally considered more influential and valuable[3].

Industry Impact and Market Relevance

Therapeutic Applications

• The JAK2 inhibitors covered by this patent have significant therapeutic applications, particularly in treating myeloproliferative disorders. This makes the patent highly relevant to the pharmaceutical industry and patients affected by these conditions[2].

Competitive Landscape

• The competitive landscape in this field is intense, with multiple pharmaceutical companies developing similar inhibitors. This patent, along with others held by Incyte Corporation, positions the company as a key player in this therapeutic area[2].

Conclusion

United States Patent 8,829,013 is a critical component of Incyte Corporation's intellectual property portfolio, focusing on JAK2 tyrosine kinase inhibitors. The patent's scope, defined by its claims, is carefully crafted to protect the company's innovations in this therapeutic area. The broader patent landscape highlights the competitive and innovative nature of the pharmaceutical industry, particularly in the development of treatments for myeloproliferative disorders.

Key Takeaways

• Patent Scope: Defined by independent and dependent claims focusing on the chemical structure of JAK2 inhibitors.
• Claims Analysis: Independent claims outline the core compounds, while dependent claims detail specific embodiments.
• Patent Landscape: Part of a series of continuation and divisional applications, indicating a strategic approach to patent portfolio management.
• Examination Process: Likely involved narrowing the scope of claims to ensure clarity and validity.
• Industry Impact: Significant therapeutic applications in treating myeloproliferative disorders.
• Competitive Landscape: Positions Incyte Corporation as a key player in the development of JAK2 inhibitors.

FAQs

Q1: What is the primary focus of United States Patent 8,829,013?

• The primary focus is on the development of inhibitors for JAK2 tyrosine kinase, particularly for treating myeloproliferative disorders.

Q2: Who are the inventors and assignees of this patent?

• The inventors include Yun-Long Li, James D. Rodgers, and others, with the assignees being Incyte Corporation and Incyte Holdings Corporation.

Q3: How does the examination process affect the scope of patent claims?

• The examination process often results in narrowing the scope of claims to ensure clarity and validity, which can improve the overall quality of the patent.

Q4: What is the significance of this patent in the pharmaceutical industry?

• This patent is significant due to its therapeutic applications in treating myeloproliferative disorders and positions Incyte Corporation as a key player in this area.

Q5: How does this patent fit into the broader patent landscape?

• It is part of a series of continuation and divisional applications, indicating a strategic approach to managing and expanding the patent portfolio in this therapeutic area.

Sources

1. United States Patent 10,610,530 B2 - Pisella et al., Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca.
2. United States Patent 9,623,029 B2 - Li et al., JAK2 tyrosine kinase inhibitors.
3. Patent Claims and Patent Scope - Hoover Institution.
4. United States Patent 9,206,187 B2 - Rodgers et al., Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as JAK inhibitors.

Drugs Protected by US Patent 8,829,013

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-001	Nov 16, 2011		RX	Yes	No	8,829,013*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No	8,829,013*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	8,829,013*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	8,829,013*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes	8,829,013*PED				Y

International Family Members for US Patent 8,829,013

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008266183
Brazil	PI0814254
Canada	2689663
China	101932582
China	103524509
Colombia	6251256